In Vivo Quantification of ERβ Expression by Pharmacokinetic Modeling: Studies with 18F-FHNP PET.

Abstract

The estrogen receptor (ER) is a target for endocrine therapy in breast cancer patients. Individual quantification of ERα and ERβ expression, rather than total ER levels, might enable better prediction of the response to treatment. We recently developed the tracer 2-18F-fluoro-6-(6-hydroxynaphthalen-2-yl)pyridin-3-ol (18F-FHNP) for assessment of ERβ levels with PET. In the current study, we investigated several pharmacokinetic analysis methods to quantify changes in ERβ availability with 18F-FHNP PET. Methods: Male nude rats were subcutaneously inoculated in the shoulder with ERα/ERβ-expressing SKOV3 human ovarian cancer cells. Two weeks after tumor inoculation, a dynamic 18F-FHNP PET scan with arterial blood sampling was acquired from rats treated with vehicle or various concentrations of estradiol (nonspecific ER agonist) or genistein (ERβ-selective agonist). Different pharmacokinetic models were applied to quantify ERβ availability in the tumor. Results: Irreversible-uptake compartmental models fitted the kinetics of 18F-FHNP uptake better than reversible models. The irreversible 3-tissue-compartment model, which included both the parent and the metabolite input function, gave results comparable to those of the irreversible 2-tissue-compartment model with only a parent input function, indicating that radioactive metabolites contributed little to the tumor uptake. Patlak graphical analysis gave metabolic rates (Ki, the irreversible uptake rate constant) comparable to compartment modeling. The Ki values correlated well with ERβ expression but not with ERα, confirming that Ki is a suitable parameter to quantify ERβ expression. SUVs at 60 min after tracer injection also correlated (r2 = 0.47; P = 0.04) with ERβ expression. A reduction in 18F-FHNP tumor uptake and Ki values was observed in the presence of estradiol or genistein. Conclusion:18F-FHNP PET enables assessment of ERβ availability in tumor-bearing rats. The most suitable parameter to quantify ERβ expression is the Ki However, a simplified static imaging protocol for determining the SUVs can be applied to assess ERβ levels.

• Authors: Inês F Antunes, Antoon T M Willemsen, Jurgen W A Sijbesma, Ate S Boerema, Aren van Waarde, Andor W J M Glaudemans, Rudi A J O Dierckx, Elisabeth G E de Vries, Geke A P Hospers, Erik F J de Vries
• Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine (J Nucl Med) Vol. 58 Issue 11 Pg. 1743-1748 (11 2017) ISSN: 1535-5667 [Electronic] United States
• PMID: 28705918 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2017 by the Society of Nuclear Medicine and Molecular Imaging.

Chemical References

• 2-fluoro-6-(6-hydroxynaphthalen-2-yl)pyridin-3-ol
• Estrogen Receptor beta
• Naphthols
• Pyridines
• Radiopharmaceuticals
• Estradiol
• Genistein

Topics

• Animals
• Cell Line, Tumor
• Estradiol (pharmacokinetics)
• Estrogen Receptor beta (agonists, biosynthesis, genetics)
• Female
• Genistein (pharmacokinetics)
• Humans
• Image Processing, Computer-Assisted
• Male
• Models, Statistical
• Naphthols (pharmacokinetics)
• Ovarian Neoplasms (diagnostic imaging)
• Positron-Emission Tomography (methods)
• Pyridines (pharmacokinetics)
• Radiopharmaceuticals (pharmacokinetics)
• Rats
• Rats, Nude
• Reproducibility of Results